Press Releases

BIOMS MEDICAL ANNOUNCES CHANGE OF AUDITOR

Edmonton, Alberta, March 28, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that effective March 24, 2006, its Board of Directors had appointed PricewaterhouseCoopers LLP, Chartered Accountants ("Pricewaterhouse") as the Company's new independent auditors, replacing the firm of Collins Barrow, Chartered Accountants ("Collins Barrow").
The decision to change auditors was not the result of any disagreement between the Company and Collins Barrow on any matter of accounting principals or practices, financial statement disclosure, or auditing scope or procedure.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.